Does Anthem (Elevance Health) Cover Finasteride?

What Is Finasteride and Why Does Coverage Vary?

Finasteride is a 5-alpha reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT). The FDA approved the 1 mg tablet for male-pattern hair loss in 1997 and the 5 mg tablet for BPH in 1992 [1]. Because finasteride has two distinct labeled indications at two different doses, insurers treat each indication separately in their formulary logic and prior authorization criteria. A plan that covers 5 mg for BPH without hassle may still require documentation before covering 1 mg for hair loss, because some payers classify hair-loss treatment as "cosmetic adjacent" even though the drug is FDA-approved for the condition.

Anthem (now operating under the Elevance Health parent brand) administers benefit plans for roughly 47 million members across its affiliated Blue Cross Blue Shield licensee states [2]. Plan designs differ substantially by state, employer group, and product line (HMO, PPO, EPO, Medicare Advantage, Medicaid). The information below reflects Anthem commercial PPO and HMO policies; Medicare Part D and Medicaid formularies follow separate federal and state-level rules.

Kaufman et al. published a key 48-week randomized trial (N=523) showing finasteride 1 mg produced statistically significant hair count increases versus placebo (P<0.001), providing the evidence base that supported FDA labeling and, by extension, insurer recognition of the indication [3]. Insurers use that label as the gateway for coverage determination.

What Formulary Tier Is Finasteride on Anthem Plans?

Generic finasteride typically lands on Tier 2 (preferred generic) on Anthem commercial formularies, meaning your copay is lower than a brand-name drug but higher than a Tier 1 generic. Some employer-sponsored plans place it on Tier 1 if the plan has negotiated aggressive generic pricing. Brand-name Propecia (1 mg) and Proscar (5 mg) generally appear on Tier 3 or higher, and Anthem's own formulary guidance usually specifies "generic required" before a brand will be considered.

You can verify your specific plan's tier placement by logging into anthem.com, entering your plan ID, and searching the drug formulary tool for "finasteride." The tier shown there determines your exact copay or coinsurance [4]. Formularies change on January 1 of each plan year, so a Tier 2 placement this year is not guaranteed next year.

The HealthRX Formulary Tier Decision Framework for Finasteride on Anthem:

1. Log into anthem.com and pull your Summary of Benefits and Coverage (SBC).
2. Search the formulary for "finasteride 1 mg" and separately for "finasteride 5 mg." Tier placement differs by dose.
3. If the tool shows a PA flag, request the Anthem Clinical Criteria document for finasteride from member services (1-800-331-1476) before your prescriber submits the PA.
4. Compare your plan's copay to the $12 average cash-pay price. For some high-deductible plans, paying cash at a discount pharmacy may cost less than using insurance during the deductible phase.

Does Anthem Require Prior Authorization for Finasteride?

Yes, prior authorization is required for finasteride on most Anthem commercial and Medicaid plans, though the clinical bar is moderate compared to specialty biologics. Anthem's PA criteria for BPH typically require confirmation of an ICD-10 code of N40.0 or N40.1, a documented prostate symptom score (commonly the International Prostate Symptom Score, or IPSS), and a provider attestation that the member is male and 18 years of age or older [5].

For androgenetic alopecia (hair loss), Anthem PA criteria generally ask for a clinical diagnosis of male-pattern baldness, confirmation that the prescriber is treating hair loss and not an off-label condition, and sometimes a note that the patient has discussed finasteride's sexual side-effect profile with their clinician. The FDA label notes that sexual adverse effects (decreased libido, ejaculatory disorder, erectile dysfunction) each occurred in roughly 1.5 to 3.8% of men in clinical trials [1].

PA requests are submitted by the prescribing clinician, not the patient. Your physician or a HealthRX-affiliated provider can submit via Anthem's provider portal, by fax, or through a third-party prior authorization service. Anthem is required by the CMS Interoperability and Prior Authorization Final Rule to respond to standard PA requests within 7 calendar days and to urgent requests within 72 hours for plans subject to that rule [6].

If Anthem approves the PA, approval periods are usually 12 months, after which the provider may need to resubmit documentation showing ongoing clinical benefit.

Does Anthem Require Step Therapy Before Approving Finasteride?

For BPH, step therapy is common. Many Anthem commercial plans require a documented trial of an alpha-1 blocker (such as tamsulosin 0.4 mg daily or doxazosin 4 to 8 mg daily) before approving finasteride, on the grounds that alpha-blockers are first-line per American Urological Association (AUA) guidelines for mild-to-moderate IPSS scores [7]. The AUA 2021 guidelines recommend combination therapy with an alpha-blocker plus a 5-alpha reductase inhibitor (5-ARI) like finasteride primarily for men with larger prostate volumes (typically greater than 30 to 40 mL) or elevated PSA suggesting gland enlargement [7].

For androgenetic alopecia, step therapy is less common. Minoxidil (topical 2% or 5%) is sometimes required as a first step, because topical minoxidil is available over the counter and is less expensive than a prescription drug. Plans that apply this logic will ask for documentation showing minoxidil was tried for at least 4 to 6 months without sufficient response before they approve finasteride.

Step therapy exceptions are available when the treating physician can demonstrate that the required first-step drug is medically inappropriate. For BPH, a physician might document that an alpha-blocker caused symptomatic orthostatic hypotension, a known class effect, making it contraindicated in a patient already on antihypertensives [8]. Anthem must review step therapy exception requests and respond within the same PA timeline rules referenced above [6].

How to Get Prior Authorization Approved: What Anthem Wants in the Chart

A well-prepared PA packet dramatically shortens approval time. For BPH, Anthem's reviewers want to see the following elements in the submitted chart notes:

• ICD-10 diagnosis code N40.1 (BPH with lower urinary tract symptoms) rather than the unspecified N40.0.
• A documented IPSS score of 8 or higher, indicating at least moderate symptoms.
• Prostate volume estimated by digital rectal exam or ultrasound, because volume greater than 30 mL strengthens the case for 5-ARI therapy per AUA guidelines [7].
• PSA value within the past 12 months. Finasteride roughly halves PSA, so baseline PSA documentation matters for ongoing monitoring [1].
• If step therapy applies, a pharmacy history or chart note documenting the alpha-blocker trial, its duration, and the reason for discontinuation or inadequacy.

For androgenetic alopecia, chart documentation should include:

• ICD-10 code L64.9 (androgenic alopecia, unspecified) or L64.8.
• A clinical description or photograph documenting the hair loss pattern (Norwood-Hamilton classification is useful).
• Patient age confirmation (finasteride is not approved for women of childbearing potential due to teratogenicity risk; the FDA label carries a Pregnancy Category X designation) [1].
• If minoxidil step therapy applies, a record of topical minoxidil use for at least 16 weeks.

Submitting an incomplete packet is the single most common reason for Anthem PA delays. Providers using Anthem's online portal receive a checklist of required fields before submission, which reduces back-and-forth.

How to Appeal a Finasteride Denial from Anthem

Anthem denials arrive with an Explanation of Benefits (EOB) or a written denial letter that states the specific clinical reason for the rejection. Common denial reasons include: step therapy not completed, diagnosis code not matching the covered indication, or a determination that the request is for an off-label use [9].

Step 1: Internal Appeal. You have the right to file an internal appeal within 180 days of the denial date (ACA-mandated timeframe). Anthem must resolve standard internal appeals within 30 days for non-urgent cases and 72 hours for expedited cases. Your physician should submit a formal letter of medical necessity that directly rebuts the denial rationale, citing the clinical evidence and AUA or dermatology society guidelines.

The AUA's 2021 guideline states: "Combination therapy with an alpha-blocker and 5-ARI is recommended for patients with LUTS/BPH who are at risk of progression" [7]. Quoting that guideline language in the appeal letter directly addresses a step-therapy denial.

The American Academy of Dermatology's position on finasteride states that it is "an effective treatment for androgenetic alopecia in men" and notes that "oral finasteride 1 mg/day" produces measurable increases in hair density at 12 months in the majority of treated men [10].

Step 2: External Independent Review. If Anthem upholds the denial internally, you can request an external review by a state-designated Independent Review Organization (IRO). Every state where Anthem operates requires an IRO option for adverse benefit determinations involving medical necessity. IRO decisions are binding on the insurer. Studies of IRO outcomes show that approximately 39 to 42% of external review decisions overturn the insurer's original denial, making this step worth pursuing [11].

Step 3: State Insurance Commissioner Complaint. Filing a complaint with your state insurance commissioner simultaneously with the IRO request adds regulatory pressure. Anthem must respond to commissioner inquiries within state-mandated timeframes, typically 15 to 30 days.

Step 4: HealthRX Provider Assistance. If your prescribing clinician is on the HealthRX platform, our administrative team can help draft the medical necessity letter and track the appeal timeline on your behalf. Providers who specialize in hormone therapy and hair loss have experience with Anthem's specific clinical criteria language.

What If Anthem Denies Finasteride and the Appeal Fails?

Cash-pay finasteride is inexpensive. Generic finasteride 1 mg (30 tablets) averages $12 to $15 per month at GoodRx-contracted pharmacies, and generic finasteride 5 mg (which some patients split into quarters for a 1.25 mg daily dose, though that practice should be discussed with a prescriber) runs similarly low. The manufacturer's list price of approximately $85 per month for brand-name Propecia makes the cash-pay generic an accessible alternative for most patients.

Merck has historically offered a savings card for Propecia for commercially insured patients, but most savings cards explicitly exclude patients using government-funded insurance (Medicare, Medicaid, TRICARE). Read the fine print of any manufacturer offer before assuming it applies to your situation.

Telehealth platforms, including HealthRX, can prescribe finasteride at transparent cash-pay prices that include the prescriber visit and medication, which bypasses the insurance PA process entirely for patients who prefer not to engage the appeals pathway.

Finasteride Efficacy: The Evidence Anthem's Reviewers Rely On

Anthem's clinical criteria are built on the same published evidence base that physicians use. Understanding that evidence helps patients and providers make the case for coverage.

For BPH, the PLESS trial (Proscar Long-term Efficacy and Safety Study, N=3,040) showed that finasteride 5 mg over 4 years reduced the risk of acute urinary retention by 57% and the need for BPH-related surgery by 55% compared to placebo [12]. That magnitude of benefit is what drives AUA guideline support for 5-ARI therapy in men with larger glands.

For androgenetic alopecia, the Kaufman et al. randomized controlled trial (N=523 to 48 weeks) showed that 83% of men treated with finasteride 1 mg maintained or increased hair count versus baseline, compared to 28% on placebo [3]. Vertex hair count increased by a mean of 107 hairs per 1-inch circle in the finasteride group versus a loss of 150 hairs in the placebo group (P<0.001) [3].

A 5-year open-label extension of the original finasteride registration trials showed that hair count gains were maintained through 5 years of continuous treatment, with 90% of treated men maintaining or exceeding baseline hair count at year 5 [13].

Long-term safety data from the Prostate Cancer Prevention Trial (PCPT, N=18,882) demonstrated that finasteride 5 mg over 7 years reduced the risk of low-grade prostate cancer detection by 24.8% compared to placebo, though the trial also showed a higher proportion of high-grade tumors in the finasteride group, a finding that has been debated extensively in the literature [14]. The FDA added updated labeling language in 2011 to address this finding [1].

Anthem Medicare Advantage and Finasteride

Medicare Advantage plans administered by Anthem follow Part D formulary rules set by CMS. Finasteride 5 mg for BPH is covered under most Anthem Medicare Advantage Part D plans; finasteride 1 mg for hair loss may or may not be covered, because Medicare does not cover drugs used primarily for cosmetic purposes under Part D. CMS's prescription drug coverage exclusions (42 CFR 423.120) list cosmetic drugs as a non-covered category, and some Medicare Advantage plans apply that logic to finasteride 1 mg [15].

Patients on Anthem Medicare Advantage who need finasteride for BPH should confirm the 5 mg dose appears on their plan's Annual Notice of Change and Part D formulary before the plan year begins. Low-Income Subsidy (LIS) beneficiaries may have different cost-sharing structures.

Anthem Medicaid and Finasteride

Anthem administers Medicaid managed care in several states under brand names like Anthem HealthKeepers Plus (Virginia) and Amerigroup (acquired by Elevance Health). Medicaid formulary placement for finasteride varies by state. Texas Medicaid, for example, covers finasteride for BPH but not for hair loss. Virginia Medicaid covers both indications with PA requirements. Patients should contact their state-specific Anthem Medicaid plan directly to verify current formulary status, because state Medicaid drug lists are updated quarterly [16].